Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Helen Rubenstein, Vice President of Investor Relations. Please go ahead. Good morning, and thank you for joining me more at Therapeutics' third quarter 2024 Financial Results Conference Call. Before we begin, I encourage everyone to go to the Investors and Media section of our website at numorotx.com, where you can find the press release related to today's call. With me today are President and Chief Executive Officer Henry Vosabrook and Chief Financial Officer Josh Pinto. Head of Research and Development Rob Lenz will join us for the Q&A portion of the call. I'd like to point out that we'll be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please review the risk factors discussed in today's press release and in our SEC filings for additional details. With that, I'll now turn the call over to Henry. Thanks, Helen. Good morning, everyone, and thank you for joining us for our first-ever quarterly conference call. Brain diseases collectively represent one of the greatest medical challenges of our generation, affecting upwards of 1.5 billion people globally. They are the leading cause of disability with a significant impact on quality of life, not only for patients, but for their caregivers, families, and society at large. We all know somebody affected by brain disease, and at Nomura, our goal is to bring the next generation of m...